Tetrakis(dimethylamino)ethylene, also known as TDAE, is a strong electron donor. It is a highly reactive compound and is typically used as a reducing agent in organic synthesis. TDAE's synthesis involves the reaction of N,N-dimethylformamide with lithium aluminum hydride. It has been studied for its potential applications in materials science, particularly in the formation of conductive polymers and organic semiconductors. The strong electron-donating properties of TDAE allow it to form charge-transfer complexes with various acceptors, leading to novel electronic and optical properties.'
tetrakis(dimethylamino)ethylene: structure in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]
| ID Source | ID |
|---|---|
| PubMed CID | 70455 |
| SCHEMBL ID | 309032 |
| MeSH ID | M0546021 |
| Synonym |
|---|
| AKOS009031439 |
| tetrakis(dimethylamino)ethylene |
| ethenetetramine, octamethyl- |
| 1-n,1-n,1-n',1-n',2-n,2-n,2-n',2-n'-octamethylethene-1,1,2,2-tetramine |
| 996-70-3 |
| tdae |
| T1221 |
| octamethylethylenetetramine |
| n,n',n'',n'''-tetramethylethylenediylidenetetraamine |
| p6737b68mn , |
| 1,1,2,2-ethenetetramine, n1,n1,n1',n1',n2,n2,n2',n2'-octamethyl- |
| einecs 213-638-1 |
| unii-p6737b68mn |
| FT-0633215 |
| tetrakis(dimethylamine)ethylene |
| tetrakis(dimethylamino)ethylene [mi] |
| n1,n1,n'1,n'1,n2,n2,n'2,n'2-octamethyl-1,1,2,2-ethenetetramine |
| tetrakis(dimethylamino)ethene |
| SCHEMBL309032 |
| n1,n1,n'1,n'1,n2,n2,n'2,n'2-octamethylethene-1,1,2,2-tetraamine , |
| DTXSID0061371 |
| mfcd00009601 |
| F17451 |
| A858438 |
| Q3546869 |
| tetra(dimethlamino)ethylene |
| tetra(dimethylamino)ethylene |
| tetrakis(dimethylamino)ethylene, >/=95% |
| Timeframe | Studies, This Drug (%) | All Drugs % |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 8 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||
According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be moderate demand-to-supply ratio for research on this compound.
| This Compound (28.51) All Compounds (24.57) |
| Publication Type | This drug (%) | All Drugs (%) |
|---|---|---|
| Trials | 0 (0.00%) | 5.53% |
| Reviews | 0 (0.00%) | 6.00% |
| Case Studies | 0 (0.00%) | 4.05% |
| Observational | 0 (0.00%) | 0.25% |
| Other | 8 (100.00%) | 84.16% |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||